CHARACTERIZATION OF PUTATIVE DRUGS FOR THE CLINICAL APPLICATIONS IN ALZHEIMER'S DISEASE

Abstract

Alzheimer’s disease is remarked as one of the world’s leading causes of dementia. In this proposal, we are trying to find out a suitable approach towards finding the cure for Alzheimer’s disease by targeting the causative molecules or by targeting the signalling pathway leading to deposition of amyloid β in Alzheimer’s disease, so that , a combinational therapy drug could be found. There are several drugs available in the market currently available for Alzheimer’s disease, out of which, we are testing a novel combination that might result in better efficient treatment as compared to the conventional drugs solo treatment. The obtained combinatorial could be further characterised as putative drugs for Alzheimer’s disease and could be scaled-up for clinical trials and applications. We are trying to find a more suitable drug which could either up-regulate the levels of insulin degrading enzyme/neprilysin, or act as inhibitors of Tau aggregation or as Acetyl cholinesterase modulators/ NMDA receptor modulator or enhance brain activity by being Neuro-protective compounds thereby reducing Oxidative stress & inflammation thus considerably reducing formation of amyloid β. Most of the available drugs show side-effects such as diarrhoea, nausea, mood changes, insomnia, fatigue, depression and loss of appetite etc. These drugs available as treatment options stabilize some of the symptoms of Alzheimer's disease for a limited period, say usually 6-12 months or longer. The drug treatments prescribed by the physicians can temporarily improve some symptoms or slow down the development of Alzheimer’s disease. So, we are trying to find the least hazardous drugs with lesser sideeffects and more effective proven results in reducing symptoms related to Alzheimer’s disease.